MOUNT PLEASANT, Mich., Nov. 10 /PRNewswire/ -- Dendritic Nanotechnologies Inc. (DNT), a company focused on the discovery, development, and commercialization of dendrimer technologies to create a new generation of innovative products for the identification and treatment of human diseases, and Lumera have entered into a joint research agreement to co-develop certain proprietary surface chemistries suitable for specific applications of Lumera’s label-free array reader, ProteomicProcessor(TM).
Under the terms of this agreement, DNT will build chemistries on proprietary Lumera surfaces, focusing efforts on using their expertise and patent holdings in the area of dendrimers. Lumera will use their proprietary instrument designs and biological systems to test and evaluate the dendrimer-based approaches. It is expected that the combined expertise of Lumera in optically active polymers, defined surfaces and label-free detection systems, and the dendrimer expertise of Dendritic Nanotechnologies, will result in unique performance features and benefits for proteomic applications. Terms of the agreement were not disclosed.
“This research agreement with Lumera is an important milestone for DNT since it represents one of the first commercial applications of our recently announced Priostar dendrimers,” said Robert Berry, DNT’s chief executive officer.
DNT’s new dendrimer technology is called Priostar(TM) and offers a significant advantage over other precision nanostructures by reducing the complexity and duration of the synthesis process. The new Priostar family of scalable, precision dendrimers breaks through previous cost barriers and addresses industry needs for nanostructures that can be manufactured in high volumes at costs attractive for a wide variety of uses.
About Lumera
Lumera is an emerging leader in the field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.
About DNT
Dendritic Nanotechnologies Inc. (DNT) is focused on the discovery, development, and commercialization of dendrimer technologies to create a new generation of innovative products for the identification and treatment of human diseases. DNT’s proprietary dendrimer platform serves as a targeted diagnostic and therapeutic delivery system for a wide variety of drugs to cancer cells and other diseases. Improved efficacy, enhanced solubility, and lower toxicity have been demonstrated for many existing drugs. DNT is committed to producing commercially viable dendrimers that can be manufactured in large quantities, and to driving down manufacturing complexity and costs. The company has a patent pending on its Priostar(TM) family of dendrimers, a novel dendrimer family that breaks through previous cost and manufacturing barriers.
Dendritic Nanotechnologies Inc.
CONTACT: Tim Cox of Zing Public Relations, +1-650-369-7784 (office), or+1-650-888-6116 (cell), or tim@zingpr.com, for Dendritic NanotechnologiesInc.
